Henrik Stage
Founder chez ADCendo ApS
Fortune : 214 344 $ au 31/03/2024
Profil
Henrik Stage founded ADCendo ApS, where he is working as Chief Financial Officer from 2021.
Mr. Stage also currently works at Biomia ApS, as Chairman from 2022, ResoTher Pharma AS, as Director, iNotify ApS, as Director, Ventac Partners A, as Partner, and Next Stage Ventures ApS, as Owner.
Mr. Stage also formerly worked at Roche Innovation Center Copenhagen A, as Chief Executive Officer from 2012 to 2014, SynAct Pharma AB, as Chief Financial Officer from 2016 to 2022, and RhoVac AB, as Chief Financial Officer.
Mr. Stage received his graduate degree from Copenhagen Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SYNACT PHARMA AB
0,75% | 20/06/2023 | 265 264 ( 0,75% ) | 214 344 $ | 31/03/2024 |
Postes actifs de Henrik Stage
| Sociétés | Poste | Début |
|---|---|---|
Ventac Partners A/S
 Ventac Partners A/S Miscellaneous Commercial ServicesCommercial Services Part of Ventac Partners GmbH, Ventac Partners A/S provides life science consulting services. The private company is based in Copenhagen, Denmark. The CEO of the Danish company is Mikael Ørum. | Corporate Officer/Principal | - |
ResoTher Pharma AS
 ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | Director/Board Member | - |
ADCendo ApS
 ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | Founder | - |
Next Stage Ventures ApS
 Next Stage Ventures ApS Miscellaneous Commercial ServicesCommercial Services Next Stage Ventures ApS is a Danish company that focuses on researching and developing biotechnology products. | Corporate Officer/Principal | - |
Anciens postes connus de Henrik Stage
| Sociétés | Poste | Fin |
|---|---|---|
| SYNACT PHARMA AB | Director of Finance/CFO | 07/01/2022 |
| CHOSA ONCOLOGY AB | Director of Finance/CFO | - |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Chief Executive Officer | 09/01/2014 |
Formation de Henrik Stage
| Copenhagen Business School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SYNACT PHARMA AB | Health Technology |
| Entreprise privées | 6 |
|---|---|
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Health Technology |
Ventac Partners A/S
Ventac Partners A/S Miscellaneous Commercial ServicesCommercial Services Part of Ventac Partners GmbH, Ventac Partners A/S provides life science consulting services. The private company is based in Copenhagen, Denmark. The CEO of the Danish company is Mikael Ørum. | Commercial Services |
RhoVac AB
 RhoVac AB BiotechnologyHealth Technology RhoVac AB opertaes as biotechnology company that engages in the research and development of immunotherapy. The firm develops therapeutic cancer vaccines. Its main focus is the development of a drug with the potential to prevent or limit the metastasis of metastatic cancers. The company was founded by Bo Anders Ljungqvist, Per Thor Straten, and Mads Hald Andersen in November 2015 and is headquartered in Lund, Sweden. | Health Technology |
Next Stage Ventures ApS
Next Stage Ventures ApS Miscellaneous Commercial ServicesCommercial Services Next Stage Ventures ApS is a Danish company that focuses on researching and developing biotechnology products. | Commercial Services |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | Health Technology |
ADCendo ApS
ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | Health Technology |
